Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin by Steffen Flindt Nielsen, Camilla Lundgreen Duus, Niels Henrik Buus, Jesper Nørgaard Bech, Frank Holden Mose

Subjects: Get full text

Effects of SGLT2i therapy on cardiac electrophysiological properties and arrhythmias in diabetic patients with implantable cardiac defibrillator by Celestino Sardu, Maria Consiglia Trotta, Ludovica Vittoria Marfella, Giovambattista D’Amico, Carmine La Marca, Ciro Mauro, Matteo Santamaria, Valerio Giordano, Fabrizio Turriziani, Concetta Rafaniello, Ferdinando Carlo Sasso, Paolo Calabro, Carmine Pizzi, Raffaele Marfella, Annalisa Capuano, Giuseppe Paolisso

Subjects: “…SGLT2i…”
Get full text

Impact of sodium-glucose cotransporter-2 inhibitors on aging biomarkers and plasma ceramide levels in type 2 diabetes: beyond glycemic control by Youssef M. Shalaby, Mohammed Moutaz Nakhal, Bachar Afandi, Bashar Al-Zohily, Lina Majed, Kukkala Kiran Kumar, Bright Starling Emerald, Bassem Sadek, Amal Akour, Nadia Akawi

Subjects: Get full text

The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives—A Narrative Review by Giuseppe Miceli, Maria Grazia Basso, Andrea Roberta Pennacchio, Elena Cocciola, Chiara Pintus, Mariagiovanna Cuffaro, Martina Profita, Giuliana Rizzo, Mariachiara Sferruzza, Antonino Tuttolomondo

Subjects: “…SGLT2-i…”
Get full text

Role of sodium-glucose cotransporter 2 inhibitors in cardiovascular events in patients with heart failure by Eva Muja, Letizia Giuseppina Floccari, Artan Simaku, Klodeta Grosha, Besim Lama, Ilirian Laçi

Subjects: “…SGLT2-I…”
Get full text

Early Recognition of Type 2 Diabetes Complications and Use of SGLT2i in Multidisciplinary Approach: Indonesian Perspective - An Expert Opinion by Aida Lydia, Ketut Suastika, Pranawa Martosuwignjo, Roy Panusunan Sibarani, Sally Aman Nasution, Soebagijo Adi Sulistijo

Subjects: Get full text

Sodium-glucose cotransporter-2 inhibitor, dapagliflozin, reverses depressive-like behavior in a mouse model of post-traumatic stress disorder by Haneen Amawi, Tayma Makhlouf, Alaa M. Hammad, Sahar Alsheyab, Rawan Alhazaimeh, F. Scott Hall, Joyeeta T. Khan, Bahaa Al-Trad, Amit K. Tiwari

Subjects: “…SGLT2i…”
Get full text

Combining sodium-glucose co-transporter-2 inhibitor with mesenchymal stem cells and brown adipose tissue (BAT) and white adipose tissue (WAT) transplantation to mitigate the progre... by Stephany Beyerstedt, Marcella L. Franco, Alanah K. G. Carlos, Jaqueline Arjona, Gleice R. Josefi-Rocha, Bruno S. Barbosa, Maria Theresa A. Balby-Rocha, Andrei Furlan da Silva, Tuany Marques Reiter Alves, Melise Oliveira Mariano, Maria Clara Soares Klein, Érika Bevilaqua Rangel

Subjects: Get full text

A study on the pharmacovigilance of various SGLT-2 inhibitors by Yanwen Dong, Yangyang Wang, Yangyang Wang, Xiaomei Lan, Xiaomei Lan, Huiyan Zeng, Huiyan Zeng

Subjects: “…SGLT2i…”
Get full text

Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives by Elina Khattab, Michaelia Kyriakou, Elena Leonidou, Stefanos Sokratous, Angeliki Mouzarou, Michael M. Myrianthefs, Nikolaos P. E. Kadoglou

Subjects: Get full text

Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production by Yan Tian, Chenxia Zhou, Qun Yan, Ziyi Li, Da Chen, Bo Feng, Jun Song

Subjects: “…SGLT2i…”
Get full text

SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes by Yun Wen, Xiaofang Zhang, Han Liu, Haowen Ye, Ruxin Wang, Caixia Ma, Tianqi Duo, Jiaxin Wang, Xian Yang, Meixin Yu, Ying Wang, Liangyan Wu, Yongting Zhao, Lihong Wang

Subjects: “…SGLT2i…”
Get full text

The impact of sodium-glucose cotransporter-2 inhibitors on breast cancer and cancer-related mortality: a systematic review and meta-analysis of randomized controlled trials by Mohammad Amin Karimi, Razieh Khadem, Alireza Haraj, Mehdi Azizabadi Farahani, Pardis Charehsaz Avari Firouzeh, Arash Azizinezhad, Hasti Kianpour Raki, Mohaddeseh Belbasi, Melika Arab Bafrani, Niloofar Deravi, Yaser Khakpour, Ali Faghih Habibi, Vahid Aghsaghloo

Subjects: “…SGLT-2i…”
Get full text

The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction? by Francesca Cinti, Renzo Laborante, Luigi Cappannoli, Cassandra Morciano, Shawn Gugliandolo, Alfredo Pontecorvi, Francesco Burzotta, Maria Donniacuo, Donato Cappetta, Giuseppe Patti, Andrea Giaccari, Domenico D’Amario

Subjects: Get full text

Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications by Basavana Goudra, Geno J. Merli, Michael Green

Subjects: Get full text

Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes by Shubham Agarwal, Mujeeb A. Basit, Michael E. Bowen, Daniel F. Heitjan, Daniel F. Heitjan, Christine Mai, Kelsea Marble, Jonathan Pak, Zichang Xiang, Ildiko Lingvay

Subjects: “…SGLT2i…”
Get full text

Empagliflozin Leads to Faster Improvement in Arterial Stiffness Compared to Dapagliflozin: A Double-Blind Clinical by Erick González Campos, Fernando Grover Páez, Carlos Gerardo Ramos Becerra, Luis Ricardo Balleza Alejandri, Daniel Osmar Suárez Rico, Ernesto Germán Cardona Muñoz, Sara Pascoe González, María Guadalupe Ramos Zavala, Alberto Beltrán Ramírez, Jesús Jonathan García Galindo, David Cardona Müller

Subjects: Get full text

Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings by Alessandro Cuttone, Vittorio Cannavò, Raouf Mastan Sheik Abdullah, Pierluigi Fugazzotto, Giada Arena, Simona Brancati, Andrea Muscarà, Carmela Morace, Cristina Quartarone, Domenica Ruggeri, Giovanni Squadrito, Giuseppina Tiziana Russo

Subjects: “…SGLT2i…”
Get full text

Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand by Lynne Chepulis, Mark Rodrigues, Han Gan, Rawiri Keenan, Tim Kenealy, Rinki Murphy, Leanne Te Karu, Jo Scott-Jones, Penny Clark, Allan Moffitt, Sara Mustafa, Ross Lawrenson, Ryan Paul

Subjects: “…SGLT2i…”
Get full text

Dapagliflozin in acute heart failure management: a systematic review and meta-analysis of safety and effectiveness by Adarsh Raja, Mata-e-Alla Dogar, Sandesh Raja, Muhammad Hamza Shuja, Shafin Bin Amin, Muskan Khelani, Urooj Fatima, Aiman Soomro, Ayesha Habiba, Iqra Mustafa, Rakhshan Zulfiqar, Muhammad Sohaib Asghar

Subjects: Get full text